2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Clinical Procedures, Emerging Technologies, Treatment Considerations, Supportive Care, Biological Therapies, Infusion, Non-Biological Therapies, Anticoagulant Drugs, Coagulant Drugs, Pharmacology, Women’s Health, Workforce, Adverse Events, Artificial Intelligence (AI), Computer Vision, Deep Learning, Generative AI, Machine Learning, Natural Language Processing, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Quality Improvement, Quality of Care, Systems-Based Hematology, Telemedicine, Value, Diseases, Bleeding and Clotting, Bleeding Disorders, Hemophilia, Thromboembolism, Thrombocytopenias, Thrombotic Disorders, VWD, Hemoglobinopathies, Sickle Cell Disease, Thalassemia, Immunology, Autoimmune Disorders, Autoimmune Hemolytic Anemia, Neutropenia, Metabolic Disorders, Iron Deficiency, Research, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Study Population, Human, Adult, Pregnant, Young Adult
PAPER

2611 Filling guideline gaps: Cost-effectiveness of iron deficiency screening in reproductive-age women at a ferritin threshold of 30 vs 50 µg/l

Aniketh Tadepalli, Daniel Wang, BS2, Manraj Sra, MD3, Kristina Rinaldi4, Sam Hirniak, PhD5, Ding Quan Ng, PhD6, Satoko Ito, MD, PhD7, Adam Cuker, MD, MS8, George Goshua, MD, SM9
1 Yale Cancer Center & Yale School of Medicine, New Haven, United States
2 Yale Cancer Center & Yale School of Medicine, New Haven, United States
3 Yale Cancer Center & Yale School of Medicine, New Haven, United States
4 Yale Cancer Center & Yale School of Medicine, New Haven, United States
5 Yale Cancer Center & Yale School of Medicine, New Haven, United States
6 Yale Cancer Center & Yale School of Medicine, New Haven, United States
7 Yale Cancer Center & Yale School of Medicine, New Haven, United States
8 University of Pennsylvania, Philadelphia, United States
9 Yale Cancer Center & Yale School of Medicine, New Haven, United States
*AT and DW are co-first authors

Introduction: Iron deficiency (ID) affects 2 billion people worldwide. This enormous public health burden is disproportionately borne by women and girls of reproductive-age, of whom nearly 40% are iron deficient – negatively affecting individual health-related quality-of-life and fetal neurocognitive development in pregnancy. In the United States (US), ID remains systematically under-recognized and under-treated due to a lack of universal screening and an inappropriately low serum ferritin-based diagnostic threshold established by the Centers for Disease Control and World Health Organization (WHO). To improve recognition, the ASH Guideline Panel on the Diagnosis and Treatment of Iron Deficiency suggested a ferritin cutoff of <30 µg/L and cited a need for cost-effectiveness evaluation of a threshold of <50 µg/L, while the American Gastroenterological Association proposed a cutoff of <45-50 µg/L. We sought to fill this gap by conducting the first cost-effectiveness analysis of ID screening and treatment at ferritin thresholds of <30 µg/L versus <50 µg/L.

Methods: We constructed a microsimulation model of reproductive age women and girls in the US to determine the cost-effectiveness of ID screening using ferritin thresholds of <50 μg/L versus <30 μg/L over a lifetime time-horizon and reporting across all accepted US willingness-to-pay (WTP) thresholds in $ per quality-adjusted life year (QALY) with a base-case WTP of $120,000/QALY. Patients entered the model at age 15 and were tested throughout their reproductive lifetimes at regular intervals commensurate with average menstrual iron losses. Serum ferritin test characteristics for ID diagnosis at each threshold were sourced from meta-analyses, while US-specific ID prevalence was sourced from the National Health and Nutrition Examination Survey (NHANES). Patients found to be deficient received oral iron; when gastrointestinal adverse effects of oral iron were intolerable, they would receive intravenous (IV) iron in subsequent cycles. The probability of oral and IV iron adverse events were drawn from randomized control trials and WHO Vigibase data. Costs of oral and IV iron treatment were sourced from the Centers for Medicare & Medicaid and GoodRx, while average annual age- and sex-specific healthcare costs were derived from the US Medical Expenditures Panel Survey (MEPS). Effectiveness, measured in QALYs, was parameterized with age-, sex-, and disease-specific EQ-5D utility values; background mortality was sourced from the National Vital Reports’ Statistics US Life Tables. We assumed that repeated IV iron exposure in patients incorrectly identified as iron deficient (i.e., false positives) would risk iatrogenic iron overload after liver iron concentration (LIC) exceeded twice the upper limit of normal with subsequent treatment cessation and negative effect on quality-of-life. Individual total body iron stores were informed across populations of both iron-sufficient and iron-deficient women sourced from NHANES with risk of transition to iron overload determined by lifetime LIC based on histologic and radiographic studies of hepatic iron deposition. The primary outcome was the incremental net monetary benefit (iNMB). To capture individual patient heterogeneity and parameter uncertainty, we conducted a two-dimensional patient- and parameter-level microsimulation with 50,000 patients each across 2,000 simultaneous probabilistic parameter draws (i.e., 100 million patients).

Results: Ferritin screening at <50 μg/L and <30 μg/L strategies accrued $205,824 and $205,675 in lifetime cost and 25.03 and 25.00 QALYs, respectively. The per-person iNMB was $3,040 [95% credible interval $550 - $5,860] in favor of the <50 μg threshold and was the cost-effective strategy in 99.5% of all probabilistic Monte Carlo iterations when compared to a threshold <30 μg/L. Deterministic sensitivity analyses showed no parameter variation which altered this conclusion.

Conclusion: Screening for ID in US women and girls of reproductive-age using a ferritin threshold of <50 μg/L, versus a ferritin threshold of <30 µg/L, is the cost-effective strategy. Our study answers a direct call for action by the ASH Guideline Panel on the Diagnosis of Iron Deficiency. Future work should continue to address this pressing need in women’s hematologic health by analyzing the real-world budget impact of universal screening implementation and its effect on longitudinal health outcomes.

Aniketh Tadepalli: No relevant conflicts of interest to declare.